TRACON Pharmaceuticals Announces Publication of Phase 1b Results for TRC105 in Combination with Inlyta® in Patients with Advanced ...
SAN DIEGO, Sept. 10, 2018 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, wet age-related macular degeneration …